enGene Therapeutics (ENGN) Return on Capital Employed (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Return on Capital Employed of 44.07% for Q2 2026, down 1002.0% year-over-year from 4.89% in Q2 2025, and up 12.13% quarter-over-quarter from 50.16% in Q1 2026.
enGene Therapeutics (ENGN) Return on Capital Employed (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Return on Capital Employed for 3 consecutive years, with 44.07% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed fell 1002.0% year-over-year to 44.07%; the TTM figure through Apr 2026 stood at 44.07% (down 1002.0% YoY), while the FY2025 annual figure was 52.56%, down 1878.0% from the prior year.
- Return on Capital Employed rose to 44.07% in Q2 2026 per ENGN's latest filing, from 50.16% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.53% in Q3 2024 and bottomed at 61.11% in Q4 2025.
- Historically, Return on Capital Employed has averaged 36.78% across 3 years, with a median of 36.36% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 1130 bps in 2025 and fell as far as 3841 bps in 2025.
- enGene Therapeutics' Return on Capital Employed stood at 22.71% in 2024, then sank by 169 bps to 61.11% in 2025, then rose by 28 bps to 44.07% in 2026.
- Business Quant data shows ENGN's Return on Capital Employed at 44.07% in Q2 2026, 50.16% in Q1 2026, and 61.11% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 7.88% |
| 10 | enGene Therapeutics | 125.50 Mn | 125.50 Mn | - | -44.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -44.07% |
| Jan 31, 2026 | -50.16% |
| Oct 31, 2025 | -61.11% |
| Jul 31, 2025 | -42.92% |
| Apr 30, 2025 | -34.05% |
| Jan 31, 2025 | -27.36% |
| Oct 31, 2024 | -22.71% |
| Jul 31, 2024 | -21.53% |
| Apr 30, 2024 | -25.27% |
| Jan 31, 2024 | -38.66% |